Fennec Pharmaceuticals Inc. (FENC) Fair Value 2026

FENC · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.7 /10

32 fundamental signals · 3 models active

Value Trap Risk

SAFE (15/100)

Quick Summary — As of 2026-08-27, Fennec Pharmaceuticals Inc. (FENC) trades at $11.77, versus a $3.46 median fair value across its 3 active models — 70.6% below the current price. QOC: 6.7/10. Value Trap Risk: 15/100 (SAFE). 3/13 models active.

Key Facts

Ticker
FENC
Price
$11.77
Quality Score
6.7/10
Value Trap Risk
15/100
Models Active
3/13
Last Updated
Strength: 3 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Fennec Pharmaceuticals Inc. (FENC) Undervalued or Overvalued in 2026?

According to CirclFi’s 3-model valuation engine, Fennec Pharmaceuticals Inc. (FENC) appears overvalued as of : the median of 3 independent fair value estimates is $3.46, 70.6% below the current price of $11.77. Estimates range from $0.43 to $5.76. FENC scores 6.7/10 on fundamental quality and 15/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. FENC’s -70.6% gap is wider than that market norm, and the Biotechnology sector median is -64.8%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Fennec Pharmaceuticals Inc. Stock in 2026? →

What Fair Value Does Each Model Give FENC?

3 Intrinsic Value Models vs. Current Price ($11.77)

Core Models (Unlocked)
Model Fair Value Upside
Scenario · High Conviction
 $0.43 -96.4%
Relative · Medium Conviction
 $5.76 -51.0%
Relative · Low Conviction
 $3.46 -70.6%

All Models Active

All 3 models are displayed above.

What Is FENC's Fair Value Range?

Spread across 3 independent models · $0.43 to $5.76

CirclFi's 3 active models place Fennec Pharmaceuticals Inc. (FENC) between $0.43 and $5.76 per share, a spread of 154% of the median. The median of that range — $3.46 — is the fair value CirclFi publishes for FENC, against a current price of $11.77.

Low · First ChicagoHigh · Regime Cross
$0.43median $3.46$5.76
Where the range comes from
Most bearish modelFirst Chicago$0.43
Most bullish modelRegime Cross-Sectional$5.76
Model agreement0 bullish · 3 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for FENC. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on FENC, not a CirclFi price target. How each model works →

What Is Fennec Pharmaceuticals Inc. (FENC) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Fennec Pharmaceuticals Inc.'s intrinsic value is estimated at $3.46. Trading at its current price of $11.77, the valuation engine raises significant caution: 3 of 3 models flag downside risk, projecting a median implied return of -70.6%. Model dispersion is worth noting: Regime Cross targets $5.76 (-51.0%), versus First Chicago at $0.43 (-96.4%). This +45.3% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About FENC?

3 of 13 models are currently active for FENC. All 3 active models suggest the stock trades above fair value. Taken together, their median fair value for FENC is $3.46 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does FENC Rank in Biotechnology?

Among 620 Biotechnology stocks, FENC ranks #72 by Quality of Company score. CirclFi's QOC score of 6.7/10 evaluates 32 fundamental signals. A score of 6.7 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

Fennec Pharmaceuticals Inc.'s positioning within the Biotechnology segment means that R&D burn rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including partnership and licensing deals — shape both the opportunity set and risk profile.

Is FENC a Value Trap?

CirclFi's Value Trap algorithm assigns FENC a score of 15/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

3 of 13 models are active for Fennec Pharmaceuticals Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Fennec Pharmaceuticals Inc. earns a quality score of 6.7/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +45.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every FENC valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across FENC's 3 active models, average confidence is 32%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Fennec Pharmaceuticals Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

RCUSArcus Biosciences, Inc.QOC 6.7ZLABZai Lab LimitedQOC 6.7CRNXCrinetics Pharmaceuticals, Inc.QOC 6.7MRKRMarker Therapeutics, Inc.QOC 6.7INSMInsmed IncorporatedQOC 6.7ZYMEZymeworks Inc.QOC 6.6HYFTMindWalk Holdings Corp.QOC 5.4RLMDRelmada Therapeutics, Inc.QOC 4.8RGBPRegen BioPharma, Inc.QOC 3.9EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: RCUS · ZLAB · CRNX · MRKR · INSM · ZYME · HYFT · RLMD · RGBP · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to FENC?

6 companies across all industries closest to FENC’s Quality of Company score of 6.7/10.

SVCOSilvaco Group, Inc.QOC 6.7BODIThe Beachbody Company, Inc.QOC 6.7DSGRDistribution Solutions Group, Inc.QOC 6.7GPREGreen Plains Inc.QOC 6.7HEPSD-Market Elektronik Hizmetler ve Ticaret A.S.QOC 6.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: SVCO · BODI · DSGR · GPRE · HEPS · NVDA

Where Does FENC Sit in CirclFi's Biotechnology Rankings?

FENC is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Fennec Pharmaceuticals Inc.’s Valuation?

What is Fennec Pharmaceuticals Inc.'s intrinsic value in 2026?

CirclFi puts Fennec Pharmaceuticals Inc. (FENC)'s intrinsic value at $3.46 — the median of 3 independent model estimates as of 2026-08-27, ranging from $0.43 to $5.76. The Quality of Company score is 6.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is FENC overvalued or undervalued right now?

At $11.77, 0 of 3 active models suggest FENC may be undervalued, while 3 indicate potential overvaluation. The median of all 3 fair value estimates is $3.46, 70.6% below the current price of $11.77 — a consensus view that FENC is overvalued. The assessment depends on which methodology best fits Fennec Pharmaceuticals Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.7 mean for FENC?

Fennec Pharmaceuticals Inc.'s QOC of 6.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on FENC?

CirclFi analyzes FENC with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 3 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on FENC?

Of the 3 models currently active on FENC, Regime Cross-Sectional is the most bullish at $5.76 per share, and First Chicago is the most bearish at $0.43. CirclFi's published fair value for FENC is the median of that range, $3.46, not either extreme. The gap between the two ends equals 154% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is FENC a value trap in 2026?

Fennec Pharmaceuticals Inc.'s Value Trap score is 15/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 3-model valuation engine, Fennec Pharmaceuticals Inc. (FENC) has a median fair value of $3.46 — 70.6% below the current price of $11.77 — as of 2026-08-27.” Source: circlfi.com/stock/FENC/ · Methodology
Primary sources for this FENC valuation
  • Financial statements: Fennec Pharmaceuticals Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001211583) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for FENC as of ; valuations recomputed .